Basal Ganglia Circuitry Models of Levodopa-Induced Dyskinesia

  • Wai Kin D. Ko
  • Matthieu Bastide
  • Erwan Bezard


L-3,4-dihydroxyphenylalanine (l-DOPA) treatment in Parkinson’s disease (PD) patients commonly leads to dyskinesia, a hyperkinetic movement disorder that remains an unsolved clinical problem. The unravelling of key pathophysiological mechanisms in PD and dyskinesia has led to updated models of the basal ganglia motor circuit, capturing nonlinear neuronal information processing in a dynamical network architecture. Our understanding into the functional organization of the basal ganglia motor system is further supported by recent computational models that focus on neuronal activations within distinct closed feedback loops. Together, these models of the basal ganglia circuitry compose a more comprehensive and detailed insight into the diverse neuronal dysfunctions in the pathophysiology of PD and LID.


l-DOPA-induced dyskinesia Parkinson’s disease Basal ganglia circuitry models 


  1. 1.
    de Rijk MC, Tzourio C, Breteler MM, Dartigues JF, Amaducci L, Lopez-Pousa S, et al. Prevalence of parkinsonism and Parkinson’s disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1997;62(1):10–5.PubMedPubMedCentralGoogle Scholar
  2. 2.
    Marsden CD. Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1994;57(6):672–81.PubMedPubMedCentralGoogle Scholar
  3. 3.
    Ehringer H, Hornykiewicz O. Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system. Klin Wochenschr. 1960;38:1236–9.PubMedGoogle Scholar
  4. 4.
    Alexander GE, Crutcher MD. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci. 1990;13(7):266–71.PubMedGoogle Scholar
  5. 5.
    Carlsson A, Lindqvist M, Magnusson T. 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature. 1957;180(4596):1200.PubMedGoogle Scholar
  6. 6.
    Friedhoff AJ, Hekimian L, Alpert M, Tobach E. Dihydroxyphenylalanine in extrapyramidal disease. JAMA. 1963;184:285–6.PubMedGoogle Scholar
  7. 7.
    Birkmayer W, Hornykiewicz O. The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia. Wien Klin Wochenschr. 1961;73:787–8.PubMedGoogle Scholar
  8. 8.
    Fahn S. “On-off” phenomenon with levodopa therapy in Parkinsonism. Clinical and pharmacologic correlations and the effect of intramuscular pyridoxine. Neurology. 1974;24(5):431–41.PubMedGoogle Scholar
  9. 9.
    Duvoisin RC. Variations in the “on-off” phenomenon. Adv Neurol. 1974;5:339–40.PubMedGoogle Scholar
  10. 10.
    Shoulson I, Glaubiger GA, Chase TN. On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients. Neurology. 1975;25(12):1144–8.PubMedGoogle Scholar
  11. 11.
    Marsden CD, Parkes JD. “On-off” effects in patients with Parkinson’s disease on chronic levodopa therapy. Lancet. 1976;1(7954):292–6.PubMedGoogle Scholar
  12. 12.
    Cotzias GC, Papavasiliou PS, Gellene R. Modification of Parkinsonism–chronic treatment with L-dopa. N Engl J Med. 1969;280(7):337–45.PubMedGoogle Scholar
  13. 13.
    Fahn S. The spectrum of levodopa-induced dyskinesias. Ann Neurol. 2000;47(4 Suppl 1):S2–9; discussion S-11.PubMedGoogle Scholar
  14. 14.
    Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord. 2001;16(3):448–58.PubMedGoogle Scholar
  15. 15.
    Rascol O. Medical treatment of levodopa-induced dyskinesias. Ann Neurol. 2000;47(4 Suppl 1):S179–88.PubMedGoogle Scholar
  16. 16.
    Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, et al. Levodopa and the progression of Parkinson’s disease. N Engl J Med. 2004;351(24):2498–508.PubMedGoogle Scholar
  17. 17.
    Chapuis S, Ouchchane L, Metz O, Gerbaud L, Durif F. Impact of the motor complications of Parkinson’s disease on the quality of life. Mov Disord. 2005;20(2):224–30.PubMedGoogle Scholar
  18. 18.
    Crossman AR, Neary D. Neuroanatomy: an illustrated colour text. Edinburgh: Churchill Livingstone; 2000.Google Scholar
  19. 19.
    Alexander GE, DeLong MR, Strick PL. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci. 1986;9:357–81.PubMedGoogle Scholar
  20. 20.
    Lavoie B, Smith Y, Parent A. Dopaminergic innervation of the basal ganglia in the squirrel monkey as revealed by tyrosine hydroxylase immunohistochemistry. J Comp Neurol. 1989;289(1):36–52.PubMedGoogle Scholar
  21. 21.
    Lavoie B, Parent A. Immunohistochemical study of the serotoninergic innervation of the basal ganglia in the squirrel monkey. J Comp Neurol. 1990;299(1):1–16.PubMedGoogle Scholar
  22. 22.
    Delfs JM, Zhu Y, Druhan JP, Aston-Jones GS. Origin of noradrenergic afferents to the shell subregion of the nucleus accumbens: anterograde and retrograde tract-tracing studies in the rat. Brain Res. 1998;806(2):127–40.PubMedGoogle Scholar
  23. 23.
    Groenewegen HJ, Galis-de Graaf Y, Smeets WJ. Integration and segregation of limbic cortico-striatal loops at the thalamic level: an experimental tracing study in rats. J Chem Neuroanat. 1999;16(3):167–85.PubMedGoogle Scholar
  24. 24.
    Castle M, Aymerich MS, Sanchez-Escobar C, Gonzalo N, Obeso JA, Lanciego JL. Thalamic innervation of the direct and indirect basal ganglia pathways in the rat: Ipsi- and contralateral projections. J Comp Neurol. 2005;483(2):143–53.PubMedGoogle Scholar
  25. 25.
    Kunzle H. Bilateral projections from precentral motor cortex to the putamen and other parts of the basal ganglia. An autoradiographic study in Macaca fascicularis. Brain Res. 1975;88(2):195–209.PubMedGoogle Scholar
  26. 26.
    Kunzle H. Projections from the primary somatosensory cortex to basal ganglia and thalamus in the monkey. Exp Brain Res. 1977;30(4):481–92.PubMedGoogle Scholar
  27. 27.
    McGeorge AJ, Faull RL. The organization of the projection from the cerebral cortex to the striatum in the rat. Neuroscience. 1989;29(3):503–37.PubMedGoogle Scholar
  28. 28.
    Romanelli P, Esposito V, Schaal DW, Heit G. Somatotopy in the basal ganglia: experimental and clinical evidence for segregated sensorimotor channels. Brain Res Brain Res Rev. 2005;48(1):112–28.PubMedGoogle Scholar
  29. 29.
    Somogyi P, Smith AD. Projection of neostriatal spiny neurons to the substantia nigra. Application of a combined Golgi-staining and horseradish peroxidase transport procedure at both light and electron microscopic levels. Brain Res. 1979;178(1):3–15.PubMedGoogle Scholar
  30. 30.
    Somogyi P, Bolam JP, Totterdell S, Smith AD. Monosynaptic input from the nucleus accumbens–ventral striatum region to retrogradely labelled nigrostriatal neurones. Brain Res. 1981;217(2):245–63.PubMedGoogle Scholar
  31. 31.
    Carpenter MB, Nakano K, Kim R. Nigrothalamic projections in the monkey demonstrated by autoradiographic technics. J Comp Neurol. 1976;165(4):401–15.PubMedGoogle Scholar
  32. 32.
    Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci. 1989;12(10):366–75.PubMedGoogle Scholar
  33. 33.
    DeLong MR. Primate models of movement disorders of basal ganglia origin. Trends Neurosci. 1990;13(7):281–5.PubMedGoogle Scholar
  34. 34.
    Clavier RM, Atmadja S, Fibiger HC. Nigrothalamic projections in the rat as demonstrated by orthograde and retrograde tracing echniques. Brain Res Bull. 1976;1(4):379–84.PubMedGoogle Scholar
  35. 35.
    Herkenham M. The afferent and efferent connections of the ventromedial thalamic nucleus in the rat. J Comp Neurol. 1979;183(3):487–517.PubMedGoogle Scholar
  36. 36.
    Deniau JM, Chevalier G. The lamellar organization of the rat substantia nigra pars reticulata: distribution of projection neurons. Neuroscience. 1992;46(2):361–77.PubMedGoogle Scholar
  37. 37.
    Deniau JM, Mailly P, Maurice N, Charpier S. The pars reticulata of the substantia nigra: a window to basal ganglia output. Prog Brain Res. 2007;160:151–72.PubMedGoogle Scholar
  38. 38.
    Gerfen CR. The neostriatal mosaic: multiple levels of compartmental organization in the basal ganglia. Annu Rev Neurosci. 1992;15:285–320.PubMedGoogle Scholar
  39. 39.
    Chevalier G, Deniau JM. Disinhibition as a basic process in the expression of striatal functions. Trends Neurosci. 1990;13(7):277–80.PubMedGoogle Scholar
  40. 40.
    Graybiel AM. Neurotransmitters and neuromodulators in the basal ganglia. Trends Neurosci. 1990;13(7):244–54.PubMedGoogle Scholar
  41. 41.
    Agid Y. Parkinson’s disease: pathophysiology. Lancet. 1991;337(8753):1321–4.PubMedGoogle Scholar
  42. 42.
    Hikosaka O, Wurtz RH. Visual and oculomotor functions of monkey substantia nigra pars reticulata. I. Relation of visual and auditory responses to saccades. J Neurophysiol. 1983;49(5):1230–53.PubMedGoogle Scholar
  43. 43.
    Hikosaka O, Wurtz RH. Visual and oculomotor functions of monkey substantia nigra pars reticulata. II. Visual responses related to fixation of gaze. J Neurophysiol. 1983;49(5):1254–67.PubMedGoogle Scholar
  44. 44.
    Hikosaka O, Wurtz RH. Visual and oculomotor functions of monkey substantia nigra pars reticulata. III. Memory-contingent visual and saccade responses. J Neurophysiol. 1983;49(5):1268–84.PubMedGoogle Scholar
  45. 45.
    Turner RS, Anderson ME. Context-dependent modulation of movement-related discharge in the primate globus pallidus. J Neurosci. 2005;25(11):2965–76.PubMedGoogle Scholar
  46. 46.
    Penney Jr JB, Young AB. Speculations on the functional anatomy of basal ganglia disorders. Annu Rev Neurosci. 1983;6:73–94.PubMedGoogle Scholar
  47. 47.
    Rascol O, Sabatini U, Chollet F, Celsis P, Montastruc JL, Marc-Vergnes JP, et al. Supplementary and primary sensory motor area activity in Parkinson’s disease. Regional cerebral blood flow changes during finger movements and effects of apomorphine. Arch Neurol. 1992;49(2):144–8.PubMedGoogle Scholar
  48. 48.
    Bezard E, Crossman AR, Gross CE, Brotchie JM. Structures outside the basal ganglia may compensate for dopamine loss in the presymptomatic stages of Parkinson’s disease. FASEB J. 2001;15(6):1092–4.PubMedGoogle Scholar
  49. 49.
    Crossman AR, Mitchell IJ, Sambrook MA. Regional brain uptake of 2-deoxyglucose in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism in the macaque monkey. Neuropharmacology. 1985;24(6):587–91.PubMedGoogle Scholar
  50. 50.
    Mitchell IJ, Cross AJ, Sambrook MA, Crossman AR. N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the monkey: neurochemical pathology and regional brain metabolism. J Neural Transm Suppl. 1986;20:41–6.PubMedGoogle Scholar
  51. 51.
    Mitchell IJ, Clarke CE, Boyce S, Robertson RG, Peggs D, Sambrook MA, et al. Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neuroscience. 1989;32(1):213–26.PubMedGoogle Scholar
  52. 52.
    Filion M, Tremblay L, Bedard PJ. Effects of dopamine agonists on the spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism. Brain Res. 1991;547(1):152–61.PubMedGoogle Scholar
  53. 53.
    Bergman H, Wichmann T, Karmon B, DeLong MR. The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism. J Neurophysiol. 1994;72(2):507–20.PubMedGoogle Scholar
  54. 54.
    Soares J, Kliem MA, Betarbet R, Greenamyre JT, Yamamoto B, Wichmann T. Role of external pallidal segment in primate parkinsonism: comparison of the effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism and lesions of the external pallidal segment. J Neurosci. 2004;24(29):6417–26.PubMedGoogle Scholar
  55. 55.
    Vila M, Levy R, Herrero MT, Ruberg M, Faucheux B, Obeso JA, et al. Consequences of nigrostriatal denervation on the functioning of the basal ganglia in human and nonhuman primates: an in situ hybridization study of cytochrome oxidase subunit I mRNA. J Neurosci. 1997;17(2):765–73.PubMedGoogle Scholar
  56. 56.
    Gerfen CR, McGinty JF, Young 3rd WS. Dopamine differentially regulates dynorphin, substance P, and enkephalin expression in striatal neurons: in situ hybridization histochemical analysis. J Neurosci. 1991;11(4):1016–31.PubMedGoogle Scholar
  57. 57.
    Henry B, Crossman AR, Brotchie JM. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson’s disease. Exp Neurol. 1998;151(2):334–42.PubMedGoogle Scholar
  58. 58.
    Ravenscroft P, Chalon S, Brotchie JM, Crossman AR. Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson’s disease: implications for dyskinesia. Exp Neurol. 2004;185(1):36–46.PubMedGoogle Scholar
  59. 59.
    Bergman H, Wichmann T, DeLong MR. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science. 1990;249(4975):1436–8.PubMedGoogle Scholar
  60. 60.
    Aziz TZ, Peggs D, Sambrook MA, Crossman AR. Lesion of the subthalamic nucleus for the alleviation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism in the primate. Mov Disord. 1991;6(4):288–92.PubMedGoogle Scholar
  61. 61.
    Wichmann T, Bergman H, DeLong MR. The primate subthalamic nucleus. III. Changes in motor behavior and neuronal activity in the internal pallidum induced by subthalamic inactivation in the MPTP model of parkinsonism. J Neurophysiol. 1994;72(2):521–30.PubMedGoogle Scholar
  62. 62.
    Guridi J, Herrero MT, Luquin MR, Guillen J, Ruberg M, Laguna J, et al. Subthalamotomy in parkinsonian monkeys. Behavioural and biochemical analysis. Brain. 1996;119(Pt 5):1717–27.PubMedGoogle Scholar
  63. 63.
    Laitinen LV, Bergenheim AT, Hariz MI. Leksell’s posteroventral pallidotomy in the treatment of Parkinson’s disease. J Neurosurg. 1992;76(1):53–61.PubMedGoogle Scholar
  64. 64.
    Baron MS, Vitek JL, Bakay RA, Green J, Kaneoke Y, Hashimoto T, et al. Treatment of advanced Parkinson’s disease by posterior GPi pallidotomy: 1-year results of a pilot study. Ann Neurol. 1996;40(3):355–66.PubMedGoogle Scholar
  65. 65.
    Gill SS, Heywood P. Bilateral dorsolateral subthalamotomy for advanced Parkinson’s disease. Lancet. 1997;350(9086):1224.PubMedGoogle Scholar
  66. 66.
    Benabid AL, Pollak P, Gross C, Hoffmann D, Benazzouz A, Gao DM, et al. Acute and long-term effects of subthalamic nucleus stimulation in Parkinson’s disease. Stereotact Funct Neurosurg. 1994;62(1–4):76–84.PubMedGoogle Scholar
  67. 67.
    Limousin P, Pollak P, Benazzouz A, Hoffmann D, Broussolle E, Perret JE, et al. Bilateral subthalamic nucleus stimulation for severe Parkinson’s disease. Mov Disord. 1995;10(5):672–4.PubMedGoogle Scholar
  68. 68.
    Limousin P, Krack P, Pollak P, Benazzouz A, Ardouin C, Hoffmann D, et al. Electrical stimulation of the subthalamic nucleus in advanced Parkinson’s disease. N Engl J Med. 1998;339(16):1105–11.PubMedGoogle Scholar
  69. 69.
    Crossman AR. A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson’s disease: implications for future strategies in treatment. Mov Disord. 1990;5(2):100–8.PubMedGoogle Scholar
  70. 70.
    Brooks DJ, Piccini P, Turjanski N, Samuel M. Neuroimaging of dyskinesia. Ann Neurol. 2000;47(4 Suppl 1):S154–8; discussion S8–9.PubMedGoogle Scholar
  71. 71.
    Rascol O, Sabatini U, Brefel C, Fabre N, Rai S, Senard JM, et al. Cortical motor overactivation in parkinsonian patients with L-dopa-induced peak-dose dyskinesia. Brain. 1998;121(Pt 3):527–33.PubMedGoogle Scholar
  72. 72.
    Mitchell IJ, Boyce S, Sambrook MA, Crossman AR. A 2-deoxyglucose study of the effects of dopamine agonists on the parkinsonian primate brain. Implications for the neural mechanisms that mediate dopamine agonist-induced dyskinesia. Brain. 1992;115(Pt 3):809–24.PubMedGoogle Scholar
  73. 73.
    Papa SM, Desimone R, Fiorani M, Oldfield EH. Internal globus pallidus discharge is nearly suppressed during levodopa-induced dyskinesias. Ann Neurol. 1999;46(5):732–8.PubMedGoogle Scholar
  74. 74.
    Boraud T, Bezard E, Guehl D, Bioulac B, Gross C. Effects of L-DOPA on neuronal activity of the globus pallidus externalis (GPe) and globus pallidus internalis (GPi) in the MPTP-treated monkey. Brain Res. 1998;787(1):157–60.PubMedGoogle Scholar
  75. 75.
    Boraud T, Bezard E, Bioulac B, Gross CE. Dopamine agonist-induced dyskinesias are correlated to both firing pattern and frequency alterations of pallidal neurones in the MPTP-treated monkey. Brain. 2001;124(Pt 3):546–57.PubMedGoogle Scholar
  76. 76.
    Merello M, Balej J, Delfino M, Cammarota A, Betti O, Leiguarda R. Apomorphine induces changes in GPi spontaneous outflow in patients with Parkinson’s disease. Mov Disord. 1999;14(1):45–9.PubMedGoogle Scholar
  77. 77.
    Lozano AM, Lang AE, Levy R, Hutchison W, Dostrovsky J. Neuronal recordings in Parkinson’s disease patients with dyskinesias induced by apomorphine. Ann Neurol. 2000;47(4 Suppl 1):S141–6.PubMedGoogle Scholar
  78. 78.
    Stefani A, Stanzione P, Bassi A, Mazzone P, Vangelista T, Bernardi G. Effects of increasing doses of apomorphine during stereotaxic neurosurgery in Parkinson’s disease: clinical score and internal globus pallidus activity. Short communication. J Neural Transm. 1997;104(8–9):895–904.PubMedGoogle Scholar
  79. 79.
    Cenci MA, Lee CS, Bjorklund A. L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur J Neurosci. 1998;10(8):2694–706.PubMedGoogle Scholar
  80. 80.
    Henry B, Crossman AR, Brotchie JM. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat. Exp Neurol. 1999;155(2):204–20.PubMedGoogle Scholar
  81. 81.
    Lundblad M, Picconi B, Lindgren H, Cenci MA. A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis. 2004;16(1):110–23.PubMedGoogle Scholar
  82. 82.
    Aubert I, Guigoni C, Li Q, Dovero S, Bioulac BH, Gross CE, et al. Enhanced preproenkephalin-B-derived opioid transmission in striatum and subthalamic nucleus converges upon globus pallidus internalis in L-3,4-dihydroxyphenylalanine-induced dyskinesia. Biol Psychiatry. 2007;61(7):836–44.PubMedGoogle Scholar
  83. 83.
    Aubert I, Guigoni C, Hakansson K, Li Q, Dovero S, Barthe N, et al. Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann Neurol. 2005;57(1):17–26.PubMedGoogle Scholar
  84. 84.
    Rascol O, Nutt JG, Blin O, Goetz CG, Trugman JM, Soubrouillard C, et al. Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease. Arch Neurol. 2001;58(2):249–54.PubMedGoogle Scholar
  85. 85.
    Calon F, Birdi S, Rajput AH, Hornykiewicz O, Bedard PJ, Di Paolo T. Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesias. J Neuropathol Exp Neurol. 2002;61(2):186–96.PubMedGoogle Scholar
  86. 86.
    Bezard E, Brotchie JM, Gross CE. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat Rev Neurosci. 2001;2(8):577–88.PubMedGoogle Scholar
  87. 87.
    Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE, et al. Development of dyskinesias in a 5-year trial of ropinirole and L-dopa. Mov Disord. 2006;21(11):1844–50.PubMedGoogle Scholar
  88. 88.
    Nadjar A, Brotchie JM, Guigoni C, Li Q, Zhou SB, Wang GJ, et al. Phenotype of striatofugal medium spiny neurons in parkinsonian and dyskinetic nonhuman primates: a call for a reappraisal of the functional organization of the basal ganglia. J Neurosci. 2006;26(34):8653–61.PubMedGoogle Scholar
  89. 89.
    Levesque M, Parent A. The striatofugal fiber system in primates: a reevaluation of its organization based on single-axon tracing studies. Proc Natl Acad Sci U S A. 2005;102(33):11888–93.PubMedPubMedCentralGoogle Scholar
  90. 90.
    Surmeier DJ, Song WJ, Yan Z. Coordinated expression of dopamine receptors in neostriatal medium spiny neurons. J Neurosci. 1996;16(20):6579–91.PubMedGoogle Scholar
  91. 91.
    Yung KK, Smith AD, Levey AI, Bolam JP. Synaptic connections between spiny neurons of the direct and indirect pathways in the neostriatum of the rat: evidence from dopamine receptor and neuropeptide immunostaining. Eur J Neurosci. 1996;8(5):861–9.PubMedGoogle Scholar
  92. 92.
    Aizman O, Brismar H, Uhlen P, Zettergren E, Levey AI, Forssberg H, et al. Anatomical and physiological evidence for D1 and D2 dopamine receptor colocalization in neostriatal neurons. Nat Neurosci. 2000;3(3):226–30.PubMedGoogle Scholar
  93. 93.
    Kerr JN, Wickens JR. Dopamine D-1/D-5 receptor activation is required for long-term potentiation in the rat neostriatum in vitro. J Neurophysiol. 2001;85(1):117–24.PubMedGoogle Scholar
  94. 94.
    Nicola SM, Hopf FW, Hjelmstad GO. Contrast enhancement: a physiological effect of striatal dopamine? Cell Tissue Res. 2004;318(1):93–106.PubMedGoogle Scholar
  95. 95.
    Joel D, Weiner I. The connections of the dopaminergic system with the striatum in rats and primates: an analysis with respect to the functional and compartmental organization of the striatum. Neuroscience. 2000;96(3):451–74.PubMedGoogle Scholar
  96. 96.
    Prensa L, Cossette M, Parent A. Dopaminergic innervation of human basal ganglia. J Chem Neuroanat. 2000;20(3–4):207–13.PubMedGoogle Scholar
  97. 97.
    Smith Y, Kieval JZ. Anatomy of the dopamine system in the basal ganglia. Trends Neurosci. 2000;23(10 Suppl):S28–33.PubMedGoogle Scholar
  98. 98.
    Sanchez-Gonzalez MA, Garcia-Cabezas MA, Rico B, Cavada C. The primate thalamus is a key target for brain dopamine. J Neurosci. 2005;25(26):6076–83.PubMedGoogle Scholar
  99. 99.
    Smith Y, Villalba R. Striatal and extrastriatal dopamine in the basal ganglia: an overview of its anatomical organization in normal and Parkinsonian brains. Mov Disord. 2008;23 Suppl 3:S534–47.PubMedGoogle Scholar
  100. 100.
    Rommelfanger KS, Wichmann T. Extrastriatal dopaminergic circuits of the Basal Ganglia. Front Neuroanat. 2010;4:139.PubMedPubMedCentralGoogle Scholar
  101. 101.
    Kreiss DS, Anderson LA, Walters JR. Apomorphine and dopamine D(1) receptor agonists increase the firing rates of subthalamic nucleus neurons. Neuroscience. 1996;72(3):863–76.PubMedGoogle Scholar
  102. 102.
    Francois C, Savy C, Jan C, Tande D, Hirsch EC, Yelnik J. Dopaminergic innervation of the subthalamic nucleus in the normal state, in MPTP-treated monkeys, and in Parkinson’s disease patients. J Comp Neurol. 2000;425(1):121–9.PubMedGoogle Scholar
  103. 103.
    Jan C, Francois C, Tande D, Yelnik J, Tremblay L, Agid Y, et al. Dopaminergic innervation of the pallidum in the normal state, in MPTP-treated monkeys and in parkinsonian patients. Eur J Neurosci. 2000;12(12):4525–35.PubMedGoogle Scholar
  104. 104.
    Obeso JA, Rodriguez-Oroz MC, Rodriguez M, Lanciego JL, Artieda J, Gonzalo N, et al. Pathophysiology of the basal ganglia in Parkinson’s disease. Trends Neurosci. 2000;23(10 Suppl):S8–19.PubMedGoogle Scholar
  105. 105.
    Leblois A, Boraud T, Meissner W, Bergman H, Hansel D. Competition between feedback loops underlies normal and pathological dynamics in the basal ganglia. J Neurosci. 2006;26(13):3567–83.PubMedGoogle Scholar
  106. 106.
    McHaffie JG, Stanford TR, Stein BE, Coizet V, Redgrave P. Subcortical loops through the basal ganglia. Trends Neurosci. 2005;28(8):401–7.PubMedGoogle Scholar
  107. 107.
    Haber SN, Fudge JL, McFarland NR. Striatonigrostriatal pathways in primates form an ascending spiral from the shell to the dorsolateral striatum. J Neurosci. 2000;20(6):2369–82.PubMedGoogle Scholar
  108. 108.
    Mallet N, Micklem BR, Henny P, Brown MT, Williams C, Bolam JP, et al. Dichotomous organization of the external globus pallidus. Neuron. 2012;74(6):1075–86.PubMedPubMedCentralGoogle Scholar
  109. 109.
    Sato F, Lavallee P, Levesque M, Parent A. Single-axon tracing study of neurons of the external segment of the globus pallidus in primate. J Comp Neurol. 2000;417(1):17–31.PubMedGoogle Scholar
  110. 110.
    Shink E, Bevan MD, Bolam JP, Smith Y. The subthalamic nucleus and the external pallidum: two tightly interconnected structures that control the output of the basal ganglia in the monkey. Neuroscience. 1996;73(2):335–57.PubMedGoogle Scholar
  111. 111.
    Obeso JA, Rodriguez-Oroz MC, Javier Blesa F, Guridi J. The globus pallidus pars externa and Parkinson’s disease. Ready for prime time? Exp Neurol. 2006;202(1):1–7.PubMedGoogle Scholar
  112. 112.
    Kita H. Globus pallidus external segment. Prog Brain Res. 2007;160:111–33.PubMedGoogle Scholar
  113. 113.
    Obeso JA, Rodriguez-Oroz MC, Benitez-Temino B, Blesa FJ, Guridi J, Marin C, et al. Functional organization of the basal ganglia: therapeutic implications for Parkinson’s disease. Mov Disord. 2008;23 Suppl 3:S548–59.PubMedGoogle Scholar
  114. 114.
    Nambu A, Tokuno H, Hamada I, Kita H, Imanishi M, Akazawa T, et al. Excitatory cortical inputs to pallidal neurons via the subthalamic nucleus in the monkey. J Neurophysiol. 2000;84(1):289–300.PubMedGoogle Scholar
  115. 115.
    Nambu A, Tokuno H, Takada M. Functional significance of the cortico-subthalamo-pallidal ‘hyperdirect’ pathway. Neurosci Res. 2002;43(2):111–7.PubMedGoogle Scholar
  116. 116.
    Lanciego JL, Gonzalo N, Castle M, Sanchez-Escobar C, Aymerich MS, Obeso JA. Thalamic innervation of striatal and subthalamic neurons projecting to the rat entopeduncular nucleus. Eur J Neurosci. 2004;19(5):1267–77.PubMedGoogle Scholar
  117. 117.
    Mena-Segovia J, Bolam JP, Magill PJ. Pedunculopontine nucleus and basal ganglia: distant relatives or part of the same family? Trends Neurosci. 2004;27(10):585–8.PubMedGoogle Scholar
  118. 118.
    Rico AJ, Barroso-Chinea P, Conte-Perales L, Roda E, Gomez-Bautista V, Gendive M, et al. A direct projection from the subthalamic nucleus to the ventral thalamus in monkeys. Neurobiol Dis. 2010;39(3):381–92.PubMedGoogle Scholar
  119. 119.
    Kita H, Tachibana Y, Nambu A, Chiken S. Balance of monosynaptic excitatory and disynaptic inhibitory responses of the globus pallidus induced after stimulation of the subthalamic nucleus in the monkey. J Neurosci. 2005;25(38):8611–9.PubMedGoogle Scholar
  120. 120.
    Marsden CD, Obeso JA. The functions of the basal ganglia and the paradox of stereotaxic surgery in Parkinson’s disease. Brain. 1994;117(Pt 4):877–97.PubMedGoogle Scholar
  121. 121.
    Obeso JA, Rodriguez MC, DeLong MR. Basal ganglia pathophysiology. A critical review. Adv Neurol. 1997;74:3–18.PubMedGoogle Scholar
  122. 122.
    Iravani MM, Costa S, Al-Bargouthy G, Jackson MJ, Zeng BY, Kuoppamaki M, et al. Unilateral pallidotomy in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets exhibiting levodopa-induced dyskinesia. Eur J Neurosci. 2005;22(6):1305–18.PubMedGoogle Scholar
  123. 123.
    Lang AE. Surgery for levodopa-induced dyskinesias. Ann Neurol. 2000;47(4 Suppl 1):S193–9; discussion S9–202.PubMedGoogle Scholar
  124. 124.
    Parkin SG, Gregory RP, Scott R, Bain P, Silburn P, Hall B, et al. Unilateral and bilateral pallidotomy for idiopathic Parkinson’s disease: a case series of 115 patients. Mov Disord. 2002;17(4):682–92.PubMedGoogle Scholar
  125. 125.
    Brown P, Oliviero A, Mazzone P, Insola A, Tonali P, Di Lazzaro V. Dopamine dependency of oscillations between subthalamic nucleus and pallidum in Parkinson’s disease. J Neurosci. 2001;21(3):1033–8.PubMedGoogle Scholar
  126. 126.
    Brown P. Oscillatory nature of human basal ganglia activity: relationship to the pathophysiology of Parkinson’s disease. Mov Disord. 2003;18(4):357–63.PubMedGoogle Scholar
  127. 127.
    Alonso-Frech F, Zamarbide I, Alegre M, Rodriguez-Oroz MC, Guridi J, Manrique M, et al. Slow oscillatory activity and levodopa-induced dyskinesias in Parkinson’s disease. Brain. 2006;129(Pt 7):1748–57.PubMedGoogle Scholar
  128. 128.
    Magill PJ, Sharott A, Bevan MD, Brown P, Bolam JP. Synchronous unit activity and local field potentials evoked in the subthalamic nucleus by cortical stimulation. J Neurophysiol. 2004;92(2):700–14.PubMedGoogle Scholar
  129. 129.
    Boraud T, Bezard E, Bioulac B, Gross CE. From single extracellular unit recording in experimental and human Parkinsonism to the development of a functional concept of the role played by the basal ganglia in motor control. Prog Neurobiol. 2002;66(4):265–83.PubMedGoogle Scholar
  130. 130.
    Engel AK, Singer W. Temporal binding and the neural correlates of sensory awareness. Trends Cogn Sci. 2001;5(1):16–25.PubMedGoogle Scholar
  131. 131.
    Engel AK, Fries P, Singer W. Dynamic predictions: oscillations and synchrony in top-down processing. Nat Rev Neurosci. 2001;2(10):704–16.PubMedGoogle Scholar
  132. 132.
    Mackay WA. Synchronized neuronal oscillations and their role in motor processes. Trends Cogn Sci. 1997;1(5):176–83.PubMedGoogle Scholar
  133. 133.
    Bar-Gad I, Morris G, Bergman H. Information processing, dimensionality reduction and reinforcement learning in the basal ganglia. Prog Neurobiol. 2003;71(6):439–73.PubMedGoogle Scholar
  134. 134.
    Raz A, Vaadia E, Bergman H. Firing patterns and correlations of spontaneous discharge of pallidal neurons in the normal and the tremulous 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine vervet model of parkinsonism. J Neurosci. 2000;20(22):8559–71.PubMedGoogle Scholar
  135. 135.
    Nini A, Feingold A, Slovin H, Bergman H. Neurons in the globus pallidus do not show correlated activity in the normal monkey, but phase-locked oscillations appear in the MPTP model of parkinsonism. J Neurophysiol. 1995;74(4):1800–5.PubMedGoogle Scholar
  136. 136.
    Wichmann T, Bergman H, DeLong MR. The primate subthalamic nucleus. I. Functional properties in intact animals. J Neurophysiol. 1994;72(2):494–506.PubMedGoogle Scholar
  137. 137.
    Bar-Gad I, Heimer G, Ritov Y, Bergman H. Functional correlations between neighboring neurons in the primate globus pallidus are weak or nonexistent. J Neurosci. 2003;23(10):4012–6.PubMedGoogle Scholar
  138. 138.
    Bergman H, Feingold A, Nini A, Raz A, Slovin H, Abeles M, et al. Physiological aspects of information processing in the basal ganglia of normal and parkinsonian primates. Trends Neurosci. 1998;21(1):32–8.PubMedGoogle Scholar
  139. 139.
    Berke JD, Okatan M, Skurski J, Eichenbaum HB. Oscillatory entrainment of striatal neurons in freely moving rats. Neuron. 2004;43(6):883–96.PubMedGoogle Scholar
  140. 140.
    Dejean C, Gross CE, Bioulac B, Boraud T. Synchronous high-voltage spindles in the cortex-basal ganglia network of awake and unrestrained rats. Eur J Neurosci. 2007;25(3):772–84.PubMedGoogle Scholar
  141. 141.
    Filion M, Tremblay L. Abnormal spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism. Brain Res. 1991;547(1):142–51.PubMedGoogle Scholar
  142. 142.
    Wichmann T, Soares J. Neuronal firing before and after burst discharges in the monkey basal ganglia is predictably patterned in the normal state and altered in parkinsonism. J Neurophysiol. 2006;95(4):2120–33.PubMedGoogle Scholar
  143. 143.
    Heimer G, Rivlin-Etzion M, Bar-Gad I, Goldberg JA, Haber SN, Bergman H. Dopamine replacement therapy does not restore the full spectrum of normal pallidal activity in the 1-methyl-4-phenyl-1,2,3,6-tetra-hydropyridine primate model of Parkinsonism. J Neurosci. 2006;26(31):8101–14.PubMedGoogle Scholar
  144. 144.
    Bevan MD, Wilson CJ, Bolam JP, Magill PJ. Equilibrium potential of GABA(A) current and implications for rebound burst firing in rat subthalamic neurons in vitro. J Neurophysiol. 2000;83(5):3169–72.PubMedGoogle Scholar
  145. 145.
    Hallworth NE, Bevan MD. Globus pallidus neurons dynamically regulate the activity pattern of subthalamic nucleus neurons through the frequency-dependent activation of postsynaptic GABAA and GABAB receptors. J Neurosci. 2005;25(27):6304–15.PubMedGoogle Scholar
  146. 146.
    Bevan MD, Hallworth NE, Baufreton J. GABAergic control of the subthalamic nucleus. Prog Brain Res. 2007;160:173–88.PubMedGoogle Scholar
  147. 147.
    Cruz AV, Mallet N, Magill PJ, Brown P, Averbeck BB. Effects of dopamine depletion on information flow between the subthalamic nucleus and external globus pallidus. J Neurophysiol. 2011;106(4):2012–23.PubMedPubMedCentralGoogle Scholar
  148. 148.
    Tachibana Y, Iwamuro H, Kita H, Takada M, Nambu A. Subthalamo-pallidal interactions underlying parkinsonian neuronal oscillations in the primate basal ganglia. Eur J Neurosci. 2011;34(9):1470–84.PubMedGoogle Scholar
  149. 149.
    Schwab BC, Heida T, Zhao Y, Marani E, van Gils SA, van Wezel RJ. Synchrony in Parkinson’s disease: importance of intrinsic properties of the external globus pallidus. Front Syst Neurosci. 2013;7:60.PubMedPubMedCentralGoogle Scholar
  150. 150.
    Marsden JF, Limousin-Dowsey P, Ashby P, Pollak P, Brown P. Subthalamic nucleus, sensorimotor cortex and muscle interrelationships in Parkinson’s disease. Brain. 2001;124(Pt 2):378–88.PubMedGoogle Scholar
  151. 151.
    Cassidy M, Mazzone P, Oliviero A, Insola A, Tonali P, Di Lazzaro V, et al. Movement-related changes in synchronization in the human basal ganglia. Brain. 2002;125(Pt 6):1235–46.PubMedGoogle Scholar
  152. 152.
    Williams D, Tijssen M, Van Bruggen G, Bosch A, Insola A, Di Lazzaro V, et al. Dopamine-dependent changes in the functional connectivity between basal ganglia and cerebral cortex in humans. Brain. 2002;125(Pt 7):1558–69.PubMedGoogle Scholar
  153. 153.
    Shimamoto SA, Ryapolova-Webb ES, Ostrem JL, Galifianakis NB, Miller KJ, Starr PA. Subthalamic nucleus neurons are synchronized to primary motor cortex local field potentials in Parkinson’s disease. J Neurosci. 2013;33(17):7220–33.PubMedPubMedCentralGoogle Scholar
  154. 154.
    Gatev P, Darbin O, Wichmann T. Oscillations in the basal ganglia under normal conditions and in movement disorders. Mov Disord. 2006;21(10):1566–77.PubMedGoogle Scholar
  155. 155.
    Moro E, Esselink RJ, Xie J, Hommel M, Benabid AL, Pollak P. The impact on Parkinson’s disease of electrical parameter settings in STN stimulation. Neurology. 2002;59(5):706–13.PubMedGoogle Scholar
  156. 156.
    Timmermann L, Wojtecki L, Gross J, Lehrke R, Voges J, Maarouf M, et al. Ten-Hertz stimulation of subthalamic nucleus deteriorates motor symptoms in Parkinson’s disease. Mov Disord. 2004;19(11):1328–33.PubMedGoogle Scholar
  157. 157.
    Fogelson N, Kuhn AA, Silberstein P, Limousin PD, Hariz M, Trottenberg T, et al. Frequency dependent effects of subthalamic nucleus stimulation in Parkinson’s disease. Neurosci Lett. 2005;382(1–2):5–9.PubMedGoogle Scholar
  158. 158.
    Hutchison WD, Lozano AM, Tasker RR, Lang AE, Dostrovsky JO. Identification and characterization of neurons with tremor-frequency activity in human globus pallidus. Exp Brain Res. 1997;113(3):557–63.PubMedGoogle Scholar
  159. 159.
    Kuhn AA, Tsui A, Aziz T, Ray N, Brucke C, Kupsch A, et al. Pathological synchronisation in the subthalamic nucleus of patients with Parkinson’s disease relates to both bradykinesia and rigidity. Exp Neurol. 2009;215(2):380–7.PubMedGoogle Scholar
  160. 160.
    Lopez-Azcarate J, Tainta M, Rodriguez-Oroz MC, Valencia M, Gonzalez R, Guridi J, et al. Coupling between beta and high-frequency activity in the human subthalamic nucleus may be a pathophysiological mechanism in Parkinson’s disease. J Neurosci. 2010;30(19):6667–77.PubMedGoogle Scholar
  161. 161.
    Brown P, Mazzone P, Oliviero A, Altibrandi MG, Pilato F, Tonali PA, et al. Effects of stimulation of the subthalamic area on oscillatory pallidal activity in Parkinson’s disease. Exp Neurol. 2004;188(2):480–90.PubMedGoogle Scholar
  162. 162.
    Foffani G, Ardolino G, Meda B, Egidi M, Rampini P, Caputo E, et al. Altered subthalamo-pallidal synchronisation in parkinsonian dyskinesias. J Neurol Neurosurg Psychiatry. 2005;76(3):426–8.PubMedPubMedCentralGoogle Scholar
  163. 163.
    Meissner W, Ravenscroft P, Reese R, Harnack D, Morgenstern R, Kupsch A, et al. Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involuntary movements in the 6-OHDA-lesioned rat in the presence of excessive extracellular striatal dopamine. Neurobiol Dis. 2006;22(3):586–98.PubMedGoogle Scholar
  164. 164.
    Brown P. Abnormal oscillatory synchronisation in the motor system leads to impaired movement. Curr Opin Neurobiol. 2007;17(6):656–64.PubMedGoogle Scholar
  165. 165.
    Brown P, Eusebio A. Paradoxes of functional neurosurgery: clues from basal ganglia recordings. Mov Disord. 2008;23(1):12–20; quiz 158.PubMedGoogle Scholar
  166. 166.
    Leblois A, Meissner W, Bioulac B, Gross CE, Hansel D, Boraud T. Late emergence of synchronized oscillatory activity in the pallidum during progressive Parkinsonism. Eur J Neurosci. 2007;26(6):1701–13.PubMedGoogle Scholar
  167. 167.
    Leblois A, Meissner W, Bezard E, Bioulac B, Gross CE, Boraud T. Temporal and spatial alterations in GPi neuronal encoding might contribute to slow down movement in Parkinsonian monkeys. Eur J Neurosci. 2006;24(4):1201–8.PubMedGoogle Scholar
  168. 168.
    Parent A, Hazrati LN. Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop. Brain Res Brain Res Rev. 1995;20(1):91–127.PubMedGoogle Scholar
  169. 169.
    Kayahara T, Nakano K. Pallido-thalamo-motor cortical connections: an electron microscopic study in the macaque monkey. Brain Res. 1996;706(2):337–42.PubMedGoogle Scholar
  170. 170.
    Hoover JE, Strick PL. The organization of cerebellar and basal ganglia outputs to primary motor cortex as revealed by retrograde transneuronal transport of herpes simplex virus type 1. J Neurosci. 1999;19(4):1446–63.PubMedGoogle Scholar
  171. 171.
    Kelly RM, Strick PL. Macro-architecture of basal ganglia loops with the cerebral cortex: use of rabies virus to reveal multisynaptic circuits. Prog Brain Res. 2004;143:449–59.PubMedGoogle Scholar
  172. 172.
    Deniau JM, Menetrey A, Charpier S. The lamellar organization of the rat substantia nigra pars reticulata: segregated patterns of striatal afferents and relationship to the topography of corticostriatal projections. Neuroscience. 1996;73(3):761–81.PubMedGoogle Scholar
  173. 173.
    Calabresi P, Centonze D, Bernardi G. Electrophysiology of dopamine in normal and denervated striatal neurons. Trends Neurosci. 2000;23(10 Suppl):S57–63.PubMedGoogle Scholar
  174. 174.
    Guthrie M, Leblois A, Garenne A, Boraud T. Interaction between cognitive and motor cortico-basal ganglia loops during decision making: a computational study. J Neurophysiol. 2013;109(12):3025–40.PubMedGoogle Scholar
  175. 175.
    Pasquereau B, Nadjar A, Arkadir D, Bezard E, Goillandeau M, Bioulac B, et al. Shaping of motor responses by incentive values through the basal ganglia. J Neurosci. 2007;27(5):1176–83.PubMedGoogle Scholar
  176. 176.
    Mink JW. The basal ganglia: focused selection and inhibition of competing motor programs. Prog Neurobiol. 1996;50(4):381–425.PubMedGoogle Scholar
  177. 177.
    Picconi B, Centonze D, Hakansson K, Bernardi G, Greengard P, Fisone G, et al. Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat Neurosci. 2003;6(5):501–6.PubMedGoogle Scholar
  178. 178.
    Belujon P, Lodge DJ, Grace AA. Aberrant striatal plasticity is specifically associated with dyskinesia following levodopa treatment. Mov Disord. 2010;25(11):1568–76.PubMedPubMedCentralGoogle Scholar
  179. 179.
    Halje P, Tamte M, Richter U, Mohammed M, Cenci MA, Petersson P. Levodopa-induced dyskinesia is strongly associated with resonant cortical oscillations. J Neurosci. 2012;32(47):16541–51.PubMedGoogle Scholar
  180. 180.
    Bastide MF, Dovero S, Charron G, Porras G, Gross CE, Fernagut PO, et al. Immediate-early gene expression in structures outside the basal ganglia is associated to l-DOPA-induced dyskinesia. Neurobiol Dis. 2013;62:179–92.PubMedGoogle Scholar
  181. 181.
    Cenci MA, Konradi C. Maladaptive striatal plasticity in L-DOPA-induced dyskinesia. Prog Brain Res. 2010;183:209–33.PubMedPubMedCentralGoogle Scholar
  182. 182.
    Guigoni C, Li Q, Aubert I, Dovero S, Bioulac BH, Bloch B, et al. Involvement of sensorimotor, limbic, and associative basal ganglia domains in L-3,4-dihydroxyphenylalanine-induced dyskinesia. J Neurosci. 2005;25(8):2102–7.PubMedGoogle Scholar
  183. 183.
    Phelix CF, Liposits Z, Paull WK. Monoamine innervation of bed nucleus of stria terminalis: an electron microscopic investigation. Brain Res Bull. 1992;28(6):949–65.PubMedGoogle Scholar
  184. 184.
    Cenci MA, Lundblad M. Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia. J Neurochem. 2006;99(2):381–92.PubMedGoogle Scholar
  185. 185.
    Carta M, Carlsson T, Munoz A, Kirik D, Bjorklund A. Involvement of the serotonin system in L-dopa-induced dyskinesias. Parkinsonism Relat Disord. 2008;14 Suppl 2:S154–8.PubMedGoogle Scholar
  186. 186.
    Navailles S, Bioulac B, Gross C, De Deurwaerdere P. Serotonergic neurons mediate ectopic release of dopamine induced by L-DOPA in a rat model of Parkinson’s disease. Neurobiol Dis. 2010;38(1):136–43.PubMedGoogle Scholar
  187. 187.
    Carta M, Bezard E. Contribution of pre-synaptic mechanisms to L-DOPA-induced dyskinesia. Neuroscience. 2011;198:245–51.PubMedGoogle Scholar
  188. 188.
    Krawczyk M, Georges F, Sharma R, Mason X, Berthet A, Bezard E, et al. Double-dissociation of the catecholaminergic modulation of synaptic transmission in the oval bed nucleus of the stria terminalis. J Neurophysiol. 2011;105(1):145–53.PubMedPubMedCentralGoogle Scholar
  189. 189.
    Carta M, Carlsson T, Kirik D, Bjorklund A. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain. 2007;130(Pt 7):1819–33.PubMedGoogle Scholar
  190. 190.
    Carta M, Carlsson T, Munoz A, Kirik D, Bjorklund A. Serotonin-dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias. Prog Brain Res. 2008;172:465–78.PubMedGoogle Scholar
  191. 191.
    Rylander D, Parent M, O’Sullivan SS, Dovero S, Lees AJ, Bezard E, et al. Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia. Ann Neurol. 2010;68(5):619–28.PubMedGoogle Scholar
  192. 192.
    Navailles S, Bioulac B, Gross C, De Deurwaerdere P. Chronic L-DOPA therapy alters central serotonergic function and L-DOPA-induced dopamine release in a region-dependent manner in a rat model of Parkinson’s disease. Neurobiol Dis. 2011;41(2):585–90.PubMedGoogle Scholar
  193. 193.
    Vollenweider I, Lang Y, Borton D, Ko D, Li Q, Courtine G, et al. Translational analysis platform for neuromotor disease research and therapeutic validation: application to Parkinson’s disease. In: Society of Neuroscience conference. San Diego; 2013. Poster 241.18/O1.Google Scholar

Copyright information

© Springer-Verlag London 2014

Authors and Affiliations

  • Wai Kin D. Ko
    • 1
    • 2
  • Matthieu Bastide
    • 3
    • 2
  • Erwan Bezard
    • 4
    • 3
    • 2
  1. 1.Department of Neurodegenerative DiseasesUniversité de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293BordeauxFrance
  2. 2.CNRS, Institut des Maladies Neurodégénératives, UMR 5293BordeauxFrance
  3. 3.Department of Neurodegenerative DiseasesUniversité de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293BordeauxFrance
  4. 4.Motac Neuroscience LtdManchesterUK

Personalised recommendations